Across TCGA pan-cancer cohorts, SSH1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SSH1 data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SSH1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SSH1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC, LIHC, and PRAD are the cancer types where SSH1 Mutation most reproducibly stratifies survival.